Answers are grounded in this paper and cite their sources.
Background: Influenza is a global health issue involving inflammatory mediators, the imbalances of which contribute to pulmonary and extrapulmonary damage. Objectives: To evaluate whether AAT1 levels are elevated in patients with severe influenza and assess its potential as a prognostic biomarker. Materials and methods: A prospective, analytical, non-interventional study was conducted on 72 patients admitted for severe influenza to the Internal Medicine Department at “Lozano Blesa” University Hospital (Zaragoza, Spain). Blood AAT1 concentrations at admission were analyzed alongside clinical and biochemical variables. Results: The mean patient age was 80.31 years (54.2% female). Overall mortality was 4.17%, one patient required ICU admission, and five had SARS-CoV-2 coinfection. Mean AAT1 concentration was 164.1 mg/dL (normal range: 100–200 mg/dL). AAT1 levels correlated significantly with leukocyte counts and C-reactive protein (r = 0.582, p < 0.001). Leukocyte counts were significantly higher in the patient requiring intensive care. Notably, AAT1 concentrations were significantly higher in patients with SARS-CoV-2 coinfection compared to non-coinfected influenza cases (p < 0.05). Conclusions: Admission AAT1 concentration does not serve as a useful prognostic biomarker in severe influenza. However, elevated AAT1 levels at diagnosis in hospitalized patients should prompt consideration of SARS-CoV-2 coinfection. Further research is warranted to clarify AAT1 involvement in influenza pathophysiology.
No takes yet. Share an insight, caveat, or question.
Franco-Burgos et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: